Geron Corp (GERN)

Price$1.56

Favorite Metrics

Price vs S&P 500 (26W)19.50%

Price vs S&P 500 (4W)5.58%

Market Capitalization$1.02B

All Metrics

Book Value / Share (Quarterly)$0.35

P/TBV (Annual)3.34x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)574.21%

Cash Flow / Share (Quarterly)$-0.17

Price vs S&P 500 (YTD)23.13%

Gross Margin (TTM)97.42%

Net Profit Margin (TTM)-45.41%

EPS (TTM)$-0.13

10-Day Avg Trading Volume20.54M

EPS Excl Extra (TTM)$-0.13

Revenue Growth (5Y)274.39%

EPS (Annual)$-0.13

ROI (Annual)-17.58%

Gross Margin (Annual)97.42%

Net Profit Margin (5Y Avg)-21993.22%

Cash / Share (Quarterly)$0.56

Revenue Growth QoQ (YoY)1.01%

ROA (Last FY)-14.64%

Revenue Growth TTM (YoY)138.83%

EBITD / Share (TTM)$-0.10

ROE (5Y Avg)-88.55%

Operating Margin (TTM)-37.30%

Cash Flow / Share (Annual)$-0.17

P/B Ratio4.54x

P/B Ratio (Quarterly)3.73x

Net Income / Employee (Annual)$-0

EV / Revenue (TTM)6.50x

Net Interest Coverage (TTM)-4.74x

ROA (TTM)-14.81%

EV / EBITDA (TTM)2596.87x

EPS Incl Extra (Annual)$-0.13

Current Ratio (Annual)4.66x

Quick Ratio (Quarterly)3.58x

3-Month Avg Trading Volume15.27M

52-Week Price Return35.48%

Revenue / Employee (TTM)$1

Tangible BV / Share (Quarterly)$2.47

P/S Ratio (Annual)5.57x

Asset Turnover (Annual)0.32x

52-Week High$2.01

Operating Margin (5Y Avg)-22678.24%

EPS Excl Extra (Annual)$-0.13

CapEx CAGR (5Y)-34.29%

Tangible BV CAGR (5Y)27.31%

26-Week Price Return28.24%

Quick Ratio (Annual)3.58x

13-Week Price Return24.44%

Total Debt / Equity (Annual)1.10x

Current Ratio (Quarterly)4.66x

Enterprise Value$1,194.561

Revenue / Share Growth (5Y)214.25%

Asset Turnover (TTM)0.33x

Book Value / Share Growth (5Y)-12.26%

Revenue / Employee (Annual)$1

Pretax Margin (Annual)-45.41%

Cash / Share (Annual)$0.56

3-Month Return Std Dev75.74%

Net Income / Employee (TTM)$-0

ROE (Last FY)-36.97%

Net Interest Coverage (Annual)-4.74x

EPS Basic Excl Extra (Annual)$-0.13

P/FCF (TTM)36.14x

Receivables Turnover (TTM)5.04x

Total Debt / Equity (Quarterly)1.10x

EPS Incl Extra (TTM)$-0.13

Receivables Turnover (Annual)0.24x

ROI (TTM)-16.77%

P/S Ratio (TTM)5.57x

Pretax Margin (5Y Avg)-21993.22%

Revenue / Share (Annual)$0.28

Tangible BV / Share (Annual)$2.47

Price vs S&P 500 (52W)0.39%

Year-to-Date Return27.27%

5-Day Price Return-2.89%

EPS Normalized (Annual)$-0.13

ROA (5Y Avg)-43.32%

Net Profit Margin (Annual)-45.41%

Month-to-Date Return12.75%

Cash Flow / Share (TTM)$-0.34

EBITD / Share (Annual)$-0.10

Operating Margin (Annual)-37.30%

LT Debt / Equity (Annual)1.03x

ROI (5Y Avg)-56.16%

LT Debt / Equity (Quarterly)1.03x

EPS Basic Excl Extra (TTM)$-0.13

P/TBV (Quarterly)3.34x

P/B Ratio (Annual)3.73x

Inventory Turnover (TTM)0.06x

Pretax Margin (TTM)-45.41%

Book Value / Share (Annual)$0.35

Price vs S&P 500 (13W)21.58%

Beta0.76x

P/FCF (Annual)111.16x

Revenue / Share (TTM)$0.28

ROE (TTM)-33.32%

52-Week Low$1.04

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

3.92

Industry Peers — Pharmaceuticals(308)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
GERNGeron Corp	5.57x	138.83%	97.42%	—	$1.56
LLYEli Lilly & Co.	13.45x	44.70%	83.04%	27.59%	$919.90
JNJJohnson & Johnson	5.82x	7.87%	67.95%	14.90%	$230.69
ABBVABBVIE INC.	5.97x	8.57%	71.62%	-2.88%	$203.71
MRKMerck & Co., Inc.	4.51x	1.31%	78.55%	21.23%	$117.10
AZNAstraZeneca PLC	5.39x	8.63%	81.31%	21.88%	$200.69
NVSNovartis AG	4.87x	8.91%	75.82%	15.26%	$150.99
NVONovo-Nordisk A/S	3.74x	6.43%	80.98%	20.66%	$40.46
ABTAbbott Laboratories	3.71x	6.59%	56.50%	8.20%	$96.00
PFEPfizer Inc.	2.50x	-1.64%	75.81%	-3.51%	$27.52
BMYBristol-Myers Squibb Co.	2.52x	-0.22%	72.63%	—	$59.13

About

Geron is a biopharmaceutical company focused on telomerase inhibitors for blood cancers. Its lead product, RYTELO (imetelstat), is approved in the United States and European Union for transfusion-dependent lower-risk myelodysplastic syndromes. The company is conducting Phase 3 testing in myelofibrosis and advancing studies in other hematologic malignancies.